Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK Limited

Rajesh Onkardas Bora

Manoranjan Panda

John F Kadow

Kap-Sun Yeung

Rajeev S Bhide

Eldon Scott Priestley

Prashantha Gunaga

Jeremy M Richter

Navnath Dnyanoba Yadav

Selvakumar Kumaravel

Mark D Wittman

Upender Velaparthi

Ramesh Kumar Sistla

Bradley C Pearce

Peiying Liu

Bireshwar Dasgupta

Chetan Padmakar Darne

Kumaravel Selvakumar

Pulicharla Nagalakshmi

Chandrasekhar Reddy Rachamreddy

Samayamunthula Venkata Satya Arun Kumar Gupta

Dibakar Mullick

Shilpa Holehatti Maheshwarappa

Erika M V Araujo

Jalathi Surendran Nair

Sakthi Kumaran Janakiraman

Arul Mozhi Selvan Subbiah Karuppiah

Bandreddy Subba Reddy

Prakash Anjanappa

Mallikarjuna Rao Mettu

Nicholas A Meanwell

Makonen Belema

John A Bender

Annapurna Pendri

Gan Wang

Van N Nguyen

Robert G Gentles

Alan Xiangdong Wang

Zhong Yang

Brett R Beno

Srinivasan Thangathirupathy

Nagalakshmi Pulicharla

Robert A Fridell

Subba Reddy Bandreddy

Mettu Mallikarjuna Rao

Arul Mozhi Subbiah Karuppiah

Shilpa Maheshwarappa Holehatti

Erika MV Araujo

Disclosed are compounds of Formula (I) or a salt thereof,wherein Ris: each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, R, L, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Substituted nitrogen containing compounds

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Benzofuran derivatives for the treatment of hepatitis C

Disclosed are compounds of Formula (I) or a salt thereof, wherein Ris (II) or (III); each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, L, L, R, R, R, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases. 

Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.

Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors

Substituted pyrazolo-piperazines as casein kinase 1 &#x3b4;/&#x3b5; inhibitors

Growing community of inventors

Bengaluru, India

Rajesh Onkardas Bora